{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:22:03Z","timestamp":1793924523493,"version":"4.8.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T00:00:00Z","timestamp":1599696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ejmech.2020.112836","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T11:08:15Z","timestamp":1599908895000},"page":"112836","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases"],"prefix":"10.1016","volume":"207","author":[{"given":"L\u00e1szl\u00f3","family":"Petri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Egyed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"Bajusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00edmea","family":"Imre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaszt\u00e1zia","family":"Het\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-8066","authenticated-orcid":false,"given":"Tam\u00e1s","family":"Martinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"\u00c1br\u00e1nyi-Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejmech.2020.112836_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.112836_bib2","doi-asserted-by":"crossref","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","author":"Abdeldayem","year":"2020","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112836_bib3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","article-title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b\/3 randomised trial","volume":"13","author":"Miller","year":"2012","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112836_bib4","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1038\/ncb0502-e127","article-title":"The origins of protein phosphorylation","volume":"4","author":"Cohen","year":"2002","journal-title":"Nat. Cell Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112836_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00018-008-8539-7","article-title":"Therapeutic protein kinase inhibitors","volume":"66","author":"Grant","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112836_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2015.213","article-title":"Kinase inhibitors and monoclonal antibodies in oncology: clinical implications","volume":"13","author":"Gharwan","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112836_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A\u00a0comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112836_bib8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.drudis.2018.01.035","article-title":"Progress with covalent small-molecule kinase inhibitors","volume":"23","author":"Zhao","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"6","key":"10.1016\/j.ejmech.2020.112836_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdw129","article-title":"Osimertinib (AZD9291)\u2014a science-driven, collaborative approach to rapid drug design and development","volume":"27","author":"Yver","year":"2016","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat. Rev. Canc."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14656566.2013.758714","article-title":"Dacomitinib, a new therapy for the treatment of non-small cell lung cancer","volume":"14","author":"Brzezniak","year":"2013","journal-title":"Expet Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112836_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J.\u00a0Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112836_bib13","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"43","key":"10.1016\/j.ejmech.2020.112836_bib14","doi-asserted-by":"crossref","first-page":"13408","DOI":"10.1002\/anie.201601091","article-title":"Targeted covalent inhibitors for drug design","volume":"55","author":"Baillie","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2020.112836_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cbpa.2014.10.021","article-title":"Covalent protein modification: the current landscape of residue-specific electrophiles","volume":"24","author":"Shannon","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112836_bib16","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1021\/acs.jcim.7b00553","article-title":"Expanding the armory: predicting and tuning covalent warhead reactivity","volume":"57","author":"Lonsdale","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112836_bib17","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and Re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112836_bib18","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.chembiol.2019.09.012","article-title":"Recent advances in selective and irreversible covalent ligand development and validation","volume":"26","author":"Zhang","year":"2019","journal-title":"Cell. Chem. Biol."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112836_bib19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/bioinformatics\/btw801","article-title":"CBinderDB: a covalent binding agent database","volume":"33","author":"Du","year":"2017","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.ejmech.2020.112836_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1039\/c2np20012k","article-title":"Electrophilic natural products and their biological targets","volume":"29","author":"Gersch","year":"2012","journal-title":"Nat. Prod. Rep."},{"issue":"25","key":"10.1016\/j.ejmech.2020.112836_bib21","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1021\/acs.biochem.7b00271","article-title":"Expanding the scope of electrophiles capable of targeting K-ras oncogenes","volume":"56","author":"McGregor","year":"2017","journal-title":"Biochemistry"},{"issue":"7325","key":"10.1016\/j.ejmech.2020.112836_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nature09472","article-title":"Quantitative reactivity profiling predicts functional cysteines in proteomes","volume":"468","author":"Weerapana","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112836_bib23","series-title":"Current Topics in Microbiology and Immunology","doi-asserted-by":"crossref","DOI":"10.1007\/82_2018_120","article-title":"Applications of reactive cysteine profiling","author":"Backus","year":"2018"},{"key":"10.1016\/j.ejmech.2020.112836_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fphar.2018.00353","article-title":"Advanced activity-based protein profiling application strategies for drug development","volume":"9","author":"Wang","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112836_bib25","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.chembiol.2020.06.016","article-title":"Chemical tools for endogenous protein labeling and profiling","volume":"27","author":"Shiraiwa","year":"2020","journal-title":"Cell. Chem. Biol."},{"issue":"9","key":"10.1016\/j.ejmech.2020.112836_bib26","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1021\/acs.jcim.8b00454","article-title":"How reactive are druggable cysteines in protein kinases?","volume":"58","author":"Awoonor-Williams","year":"2018","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112836_bib27","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1021\/acs.jmedchem.6b01815","article-title":"Determining cysteines available for covalent inhibition across the human kinome","volume":"60","author":"Zhao","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2020.112836_bib28","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.1021\/jacs.8b13248","article-title":"Assessing lysine and cysteine reactivities for designing targeted covalent kinase inhibitors","volume":"141","author":"Liu","year":"2019","journal-title":"J.\u00a0Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112836_bib29","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1021\/acs.jcim.7b00163","article-title":"Statistical analysis and prediction of covalent ligand targeted cysteine residues","volume":"57","author":"Zhang","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wcms.19","article-title":"The electrostatic potential: an overview","volume":"1","author":"Murray","year":"2011","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112836_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1021\/cr00036a002","article-title":"Molecular electrostatics","volume":"95","author":"Naray-Szabo","year":"1995","journal-title":"Chem. Rev."},{"issue":"80","key":"10.1016\/j.ejmech.2020.112836_bib32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science1108367","article-title":"Structural bioinformatics-based design of selective, irreversible kinase inhibitors","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2020.112836_bib33","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1021\/jm101396q","article-title":"Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors","volume":"54","author":"Leproult","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chembiol.2012.12.006","article-title":"Developing irreversible inhibitors of the protein kinase cysteinome","volume":"20","author":"Liu","year":"2013","journal-title":"Chem. Biol."},{"issue":"11","key":"10.1016\/j.ejmech.2020.112836_bib35","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbapap.2017.05.009","article-title":"Modeling covalent-modifier drugs","volume":"1865","author":"Awoonor-Williams","year":"2017","journal-title":"Biochim. Biophys. Acta Protein Proteonomics"},{"issue":"9","key":"10.1016\/j.ejmech.2020.112836_bib36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrd.2016.109","article-title":"Twenty years on: the impact of fragments on drug discovery","volume":"15","author":"Erlanson","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.112836_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.03.016","article-title":"Covalent fragment libraries in drug discovery","author":"Keeley","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"23","key":"10.1016\/j.ejmech.2020.112836_bib38","doi-asserted-by":"crossref","first-page":"11726","DOI":"10.1021\/acs.joc.6b02188","article-title":"Kinetics and thermodynamics of reversible thiol additions to mono- and diactivated michael acceptors: implications for the design of drugs that bind covalently to cysteines","volume":"81","author":"Krenske","year":"2016","journal-title":"J.\u00a0Org. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2020.112836_bib39","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1021\/jm501412a","article-title":"Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors","volume":"57","author":"Flanagan","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2020.112836_bib40","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1021\/acs.jmedchem.5b01018","article-title":"Systematic study of the glutathione (GSH) reactivity of N -arylacrylamides: 1. Effects of aryl substitution","volume":"58","author":"Cee","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112836_bib41","doi-asserted-by":"crossref","first-page":"115357","DOI":"10.1016\/j.bmc.2020.115357","article-title":"Comparative reactivity analysis of small-molecule thiol surrogates","volume":"28","author":"Petri","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2020.112836_bib42","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1021\/ci200608b","article-title":"Thermodynamics of fragment binding","volume":"52","author":"Ferenczy","year":"2012","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"6","key":"10.1016\/j.ejmech.2020.112836_bib43","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1021\/cr040109f","article-title":"Electrophilicity index","volume":"106","author":"Chattaraj","year":"2006","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2020.112836_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A\u00a0road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"\u00c1br\u00e1nyi-Balogh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"80","key":"10.1016\/j.ejmech.2020.112836_bib45","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2020.112836_bib46","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.7717\/peerj.126","article-title":"A\u00a0stand-alone and web-accessible tool to annotate the human protein kinome tree","volume":"1","author":"Chartier","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.ejmech.2020.112836_bib47","series-title":"Progress in Medicinal Chemistry","doi-asserted-by":"crossref","DOI":"10.1016\/bs.pmch.2018.12.002","article-title":"Covalent binders in drug discovery","author":"Vasudevan","year":"2019"},{"issue":"8","key":"10.1016\/j.ejmech.2020.112836_bib48","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1074\/jbc.M114.595181","article-title":"Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol","volume":"290","author":"Goedken","year":"2015","journal-title":"J.\u00a0Biol. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2020.112836_bib49","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1021\/acs.jmedchem.5b00710","article-title":"Development of selective covalent Janus kinase 3 inhibitors","volume":"58","author":"Tan","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2020.112836_bib50","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1016\/j.bmcl.2017.09.023","article-title":"Discovery of highly potent, selective, covalent inhibitors of JAK3","volume":"27","author":"Kempson","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"12","key":"10.1016\/j.ejmech.2020.112836_bib51","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2020.112836_bib52","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a Janus kinase 3 (JAK3) specific inhibitor 1-((2 S ,5 R )-5-((7 H -Pyrrolo[2,3- d ]Pyrimidin-4-Yl)Amino)-2-Methylpiperidin-1-Yl)Prop-2-En-1-One (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2020.112836_bib53","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1016\/j.bmcl.2017.07.079","article-title":"Recent advances in JAK3 inhibition: isoform selectivity by covalent cysteine targeting","volume":"27","author":"Forster","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11030-017-9803-2","article-title":"Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors","volume":"22","author":"He","year":"2018","journal-title":"Mol. Divers."},{"issue":"24","key":"10.1016\/j.ejmech.2020.112836_bib55","doi-asserted-by":"crossref","first-page":"12351","DOI":"10.1021\/acs.joc.5b02226","article-title":"Tuning the electronic properties of 2-cyano-3-phenylacrylamide derivatives","volume":"80","author":"Gunasekar","year":"2015","journal-title":"J.\u00a0Org. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2020.112836_bib56","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nchembio.1666","article-title":"Covalent docking of large libraries for the discovery of chemical probes","volume":"10","author":"London","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112836_bib57","doi-asserted-by":"crossref","DOI":"10.3892\/or.2019.6988","article-title":"MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells","author":"Ren","year":"2019","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2020.112836_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1535-7163.MCT-18-0819","article-title":"Maternal embryonic leucine zipper kinase (MELK), a potential therapeutic target for neuroblastoma","volume":"18","author":"Chlenski","year":"2019","journal-title":"Mol. Canc. Therapeut."},{"issue":"1","key":"10.1016\/j.ejmech.2020.112836_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/medicina56010001","article-title":"Inhibition of MELK protooncogene as an innovative treatment for intrahepatic cholangiocarcinoma","volume":"56","author":"Cigliano","year":"2019","journal-title":"Medicina (B Aires)"},{"issue":"1","key":"10.1016\/j.ejmech.2020.112836_bib60","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/neuonc\/noz151","article-title":"MEK\/MELK inhibition and blood\u2013brain barrier deficiencies in atypical teratoid\/rhabdoid tumors","volume":"22","author":"Meel","year":"2020","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2020.112836_bib61","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1074\/jbc.RA119.011083","article-title":"Mass spectrometry\u2013based selectivity profiling identifies a highly selective inhibitor of the kinase MELK that delays mitotic entry in cancer cells","volume":"295","author":"McDonald","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112836_bib62","series-title":"Gaussian 09 (Revision A.02)","author":"Frisch","year":"2009"},{"issue":"10","key":"10.1016\/j.ejmech.2020.112836_bib63","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1021\/jz100247x","article-title":"Local electrophilicity predicts the toxicity-relevant reactivity of michael acceptors","volume":"1","author":"Wondrousch","year":"2010","journal-title":"J.\u00a0Phys. Chem. Lett."},{"issue":"10","key":"10.1016\/j.ejmech.2020.112836_bib65","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1021\/acs.jmedchem.6b00052","article-title":"Toward the validation of maternal embryonic leucine zipper kinase: discovery, optimization of highly potent and selective inhibitors, and preliminary biology insight","volume":"59","author":"Tour\u00e9","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112836_bib66","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"Zhu","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"issue":"7","key":"10.1016\/j.ejmech.2020.112836_bib67","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2020.112836_bib68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A\u00a0hierarchical approach to all-atom protein loop prediction","volume":"55","author":"Jacobson","year":"2004","journal-title":"Proteins Struct. Funct. Bioinforma."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420308084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:23:37Z","timestamp":1759328617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420308084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":67,"alternative-id":["S0223523420308084"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112836","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112836","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112836"}}